Lonza sells capsules, health ingredients business to Lone Star Funds for CHF2.3B
Lonza divests capsules and health ingredients business to Lone Star Funds for CHF 2.3 billion, finalizing its shift to a pure-play CDMO model by H2 2026.
chemweek · 2026-03-09 20:41 UTC